{"entity":{"id":"rivaroxaban","kind":"drug","name":"Rivaroxaban","aka":[],"tldr":"Rivaroxaban is a blood-thinning tablet used to treat a clot in many people with cancer, and to prevent clots in some people starting chemotherapy who are at higher risk.","summary":"The Xarelto label covers atrial fibrillation, treatment of DVT and pulmonary embolism and reduction of recurrence, prophylaxis after hip or knee replacement and in acutely ill medical patients, and coronary and peripheral artery disease. ITAC 2022 accepts rivaroxaban for initial and maintenance treatment of VTE in people with cancer without a high risk of gastrointestinal or genitourinary bleeding (1A), and recommends rivaroxaban or apixaban for primary prophylaxis in ambulatory people on systemic anticancer therapy with a Khorana score of 2 or more (1B), including locally advanced or metastatic pancreatic cancer (1B). The 2023 ASCO update added rivaroxaban and apixaban as options for extended prophylaxis after cancer surgery (weak recommendation). The NDA was first approved on 1 July 2011.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Rivaroxaban","links":[{"label":"US label (DailyMed): Xarelto","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610"},{"label":"Farge et al., 2022 international clinical practice guidelines (ITAC) for the treatment and prophylaxis of venous thromboembolism in patients with cancer (Lancet Oncol 2022)","url":"https://doi.org/10.1016/S1470-2045(22)00160-7"},{"label":"Key et al., Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update (J Clin Oncol 2023)","url":"https://doi.org/10.1200/JCO.23.00294"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["apixaban","edoxaban","enoxaparin"],"cancers":[],"sections":[],"technologies":["cancer-associated-thrombosis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["vte"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-key-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Xarelto","modality":"Direct oral anticoagulant (factor Xa inhibitor, tablet)","supportive":true,"mechanism":"A direct, oral inhibitor of activated factor X.","approvals":[{"region":"US","year":2011,"indication":"Atrial fibrillation; treatment of DVT and PE and reduction of recurrence; VTE prophylaxis after hip or knee replacement and in acutely ill medical patients; coronary and peripheral artery disease","note":"Year is the original NDA 022406 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rivaroxaban/","neighbours":{"drug":[{"id":"apixaban","kind":"drug","name":"Apixaban","route":"/drugs/apixaban/"},{"id":"edoxaban","kind":"drug","name":"Edoxaban","route":"/drugs/edoxaban/"},{"id":"enoxaparin","kind":"drug","name":"Enoxaparin","route":"/drugs/enoxaparin/"}],"technology":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/"}],"term":[{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/"}],"paper":[{"id":"paper-key-j-clin-oncol","kind":"paper","name":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-key-j-clin-oncol/"}]}}